Stockreport

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

NovaBay Pharmaceuticals, Inc.  (NBY) 
NASDAQ:AMEX Investor Relations: novabay.com/investors
PDF Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova® physician dispensed and OTC channels, and from bran [Read more]